Cited by 2,497Cell death mechanisms and regulationToxin Mechanisms and ImmunotoxinsCancer-related Molecular Pathways

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Walczak, Henning, Miller, Robert E., Ariail, Kiley, Gliniak, Brian, Griffith, Thomas S., Kubin, Marek, Chin, Wilson, Jones, Jon, Woodward, Anne, Le, Tiep, Smith, Craig, Smolak, Pam, Goodwin, Raymond G., Rauch, Charles T., Schuh, JoAnn C.L., Lynch, David H.·1999·Nature Medicine

DOI 10.1038/5517

Open this paper in CoChat — free account

Abstract

To evaluate the utility of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a cancer therapeutic, we created leucine zipper (LZ) forms of human (hu) and murine (mu) TRAIL to promote and stabilize the formation of trimers. Both were biologically active, inducing apoptosis of both human and murine target cells in vitro with similar specific activities. In contrast to the fulminant hepatotoxicity of LZ-huCD95L in vivo, administration of either LZ-huTRAIL or LZ-muTRAIL did not seem toxic to normal tissues of mice. Finally, repeated treatments with LZ-huTRAIL actively suppressed growth of the TRAIL-sensitive human mammary adenocarcinoma cell line MDA-231 in CB.17 (SCID) mice, and histologic examination of tumors from SCID mice treated with LZ-huTRAIL demonstrated clear areas of apoptotic necrosis within 9-12 hours of injection.

Integrity signals

Registry

Crossref · 10.1038/5517

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Apoptosis by Death Factor
Nagata, S. (1997) · Cell · doi:10.1016/s0092-8674(00)81874-7 · Cited by 4,934
Bone marrow transplant
Joyce, A. (1989) · Nursing Children and Young People · doi:10.7748/paed.1.6.21.s21 · Cited by 3,408
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Self-citation
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
Griffith, T. S., Brunner, T., Fletcher, S. M., Green, D. R., & Ferguson, T. A. (1995) · Science · doi:10.1126/science.270.5239.1189 · Cited by 1,990
Self-citation
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,909
Self-citation
Tumor Necrosis Factor (TNF)
Old, L. J. (1985) · Science · doi:10.1126/science.2413547 · Cited by 1,885
Lethal effect of the anti-Fas antibody in mice
Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., & Nagata, S. (1993) · Nature · doi:10.1038/364806a0 · Cited by 1,881
Autocrine T-cell suicide mediated by APO-1/(Fas/CD95)
Dhein, J., Walczak, H., Bäumler, C., Debatin, K., & Krammer, P. (1995) · Nature · doi:10.1038/373438a0 · Cited by 1,814
Self-citation
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,777
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice
Kägi, D., Ledermann, B., Bürki, K., Seiler, P. J., Odermatt, B., Olsen, K. J., Podack, E. R., Zinkernagel, R. M., & Hengartner, H. (1994) · Nature · doi:10.1038/369031a0 · Cited by 1,758

Flagged first, then by citations

Show all 48 references

Sorted by citations

The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Death and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature reviews. Cancer · doi:10.1038/nrc776 · Cited by 2,073
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1252 · Cited by 1,660
Targeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature reviews. Cancer · doi:10.1038/nrc821 · Cited by 1,351
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1123 · Cited by 1,165
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905
TRAIL and apoptosis induction by TNF-family death receptors
Wang, S., & El‐Deiry, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1207232 · Cited by 869
Apo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 856
Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
Jo, M., Kim, T., Seol, D., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 841
The TRAIL apoptotic pathway in cancer onset, progression and therapy
Johnstone, R. W., Frew, A. J., & Smyth, M. J. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2465 · Cited by 843
Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
FADD/MORT1 and Caspase-8 Are Recruited to TRAIL Receptors 1 and 2 and Are Essential for Apoptosis Mediated by TRAIL Receptor 2
Sprick, M. R., Weigand, M. A., Rieser, E., Rauch, C. T., Juo, P., Blenis, J., Krammer, P. H., & Walczak, H. (2000) · Immunity · doi:10.1016/s1074-7613(00)80211-3 · Cited by 809
Self-citation
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
Takeda, K., Hayakawa, Y., Smyth, M. J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita∥, H., & Okumura, K. (2001) · Nature Medicine · doi:10.1038/83416 · Cited by 771
Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo
Fulda, S., Wick, W., Weller, M., & Debatin, K. (2002) · Nature Medicine · doi:10.1038/nm735 · Cited by 736
RETRACTED: miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 Downregulation
Garofalo, M., Leva, G. D., Romano, G., Nuovo, G. J., Suh, S., Ngankeu, A., Taccioli, C., Pichiorri, F., Alder, H., Secchiero, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.014 · Cited by 743
Retracted
Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.09.011 · Cited by 731
Lysosomes in cell death
Guicciardi, M. E., Leist, M., & Gores, G. J. (2004) · Oncogene · doi:10.1038/sj.onc.1207512 · Cited by 731
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D. A., Shahrokh, Z., Marsters, S. A., Achilles, K., Shih, D., Mounho, B. J., Hillan, K. J., Tótpál, K., DeForge, L. E., Schow, P. W., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Self-citation
Apoptosis: a basic biological phenomenon with wide‐ranging implications in human disease
Fadeel, B., & Orrenius, S. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01570.x · Cited by 727
Apoptosis and Necrosis in the Liver: A Tale of Two Deaths?
Malhi, H., Gores, G. J., & Lemasters, J. J. (2006) · Hepatology · doi:10.1002/hep.21062 · Cited by 694
Life and death by death receptors
Guicciardi, M. E., & Gores, G. J. (2009) · The FASEB Journal · doi:10.1096/fj.08-111005 · Cited by 727
From bench to clinic with apoptosis-based therapeutic agents
Nicholson, D. W. (2000) · Nature · doi:10.1038/35037747 · Cited by 685
Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II
Wang, J., Zheng, L., Lobito, A. A., Chan, F. K.-M., Dale, J. K., Sneller, M. C., Xu, Y., Puck, J. M., Straus, S. E., & Lenardo, M. J. (1999) · Cell · doi:10.1016/s0092-8674(00)80605-4 · Cited by 644
The CD95 (APO-1/Fas) and the TRAIL (APO-2L) Apoptosis Systems
Walczak, H., & Krammer, P. H. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4840 · Cited by 624
Self-citation
Increased Susceptibility to Tumor Initiation and Metastasis in TNF-Related Apoptosis-Inducing Ligand-Deficient Mice
Cretney, E., Takeda, K., Yagita∥, H., Glaccum, M. B., Peschon, J. J., & Smyth, M. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1356 · Cited by 615
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Álvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2004) · Nature Medicine · doi:10.1038/nm1161 · Cited by 619
Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression
Luo, J., Maeda, S., Hsu, L.-C., Yagita∥, H., & Karin, M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.012 · Cited by 598
Cellular FLICE-inhibitory Protein Splice Variants Inhibit Different Steps of Caspase-8 Activation at the CD95 Death-inducing Signaling Complex
Krueger, A., Schmitz, I., Baumann, S., Krammer, P. H., & Kirchhoff, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101780200 · Cited by 565
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
von Karstedt, S., Montinaro, A., & Walczak, H. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.28 · Cited by 556
Self-citation
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy
Almasan, A., & Ashkenazi, A. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00029-7 · Cited by 547
Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 544
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy
Chinnaiyan, A. M., Prasad, U., Shankar, S., Hamstra, D. A., Shanaiah, M., Chenevert, T. L., Ross, B. D., & Rehemtulla, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.030545097 · Cited by 534
Chemotherapeutic Approaches for Targeting Cell Death Pathways
Ricci, M., & Zong, W. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-342 · Cited by 523
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis
Smyth, M. J., Cretney, E., Takeda, K., Wiltrout, R. H., Sedger, L. M., Kayagaki, N., Yagita∥, H., & Okumura, K. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.661 · Cited by 512
Anticancer therapy targeting the apoptotic pathway
Hu, W., & Kavanagh, J. J. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01277-4 · Cited by 511
Tumor-cell resistance to death receptor–induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax
LeBlanc, H. N., Lawrence, D. A., Varfolomeev, E. E., Tótpál, K., Morlan, J., Schow, P. W., Fong, S. E., SCHWALL, R. H., Sinicropi, D. V., & Ashkenazi, A. (2002) · Nature Medicine · doi:10.1038/nm0302-274 · Cited by 500
Death receptors in chemotherapy and cancer
Debatin, K., & Krammer, P. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207558 · Cited by 505
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2018) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 529
Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL
Griffith, T. S., Wiley, S. R., Kubin, M. Z., Sedger, L. M., Maliszewski, C. R., & Fanger, N. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.8.1343 · Cited by 477
Self-citation
Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development
Takeda, K., Smyth, M. J., Cretney, E., Hayakawa, Y., Kayagaki, N., Yagita∥, H., & Okumura, K. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011171 · Cited by 462
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.81 · Cited by 471
Self-citation
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLOPreprint
Deng, Y., Lin, Y., & Wu, X. (2002) · Genes & Development · doi:10.1101/gad.949602 · Cited by 459
A fate worse than death: apoptosis as an oncogenic process
Ichim, G., & Tait, S. W. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.58 · Cited by 451
Preclinical Studies to Predict the Disposition of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Humans: Characterization of in Vivo Efficacy, Pharmacokinetics, and Safety
Kelley, S. K., Harris, L. A., Xie, D., DeForge, L. E., Tótpál, K., Bussiere, J., & Fox, J. A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29298-3 · Cited by 444
Natural Killer Cells and Cancer
Wu, J., & Lanier, L. L. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)90004-2 · Cited by 435
Triggering Cell Death
Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M. H., O'Connell, M., Kelley, R. F., Ashkenazi, A., & de Vos, A. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80207-5 · Cited by 447
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 440
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage
Dunn, C., Brunetto, M. R., Reynolds, G. M., Christophides, T., Kennedy, P. T. F., Lampertico, P., Das, A., Lopes, A. R., Borrow, P., Williams, K. T., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061287 · Cited by 421
Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways
Suliman, A., Lam, A., Datta, R., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204282 · Cited by 417
Mesenchymal Stem Cell Delivery of TRAIL Can Eliminate Metastatic Cancer
Loebinger, M. R., Eddaoudi, A., Davies, D., & Janes, S. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4698 · Cited by 417
Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail)
Fanger, N. A., Maliszewski, C. R., Schooley, K., & Griffith, T. S. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.8.1155 · Cited by 415
Self-citation
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
Lacey, D. L., Tan, H. L., Lu, J., Kaufman, S., Van, G., Qiu, W., Rattan, A., Scully, S., Fletcher, F., Juan, T., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64556-7 · Cited by 391
Targeting apoptotic caspases in cancer
Boice, A., & Bouchier‐Hayes, L. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2020.118688 · Cited by 406
Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression
Fulda, S., Meyer, É., & Debatin, K. (2002) · Oncogene · doi:10.1038/sj.onc.1205258 · Cited by 394
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
Mitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P. G. G., Schlossman, R. L., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 391
Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
Nagane, M., Pan, G., Weddle, J. J., Dixit, V. M., Cavenee, W. K., & Huang, H. (2000) · PubMed · Cited by 387
Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim, K., Fisher, M. J., Xu, S., & El‐Deiry, W. S. (2000) · PubMed · Cited by 376
Modes of Regulated Cell Death in Cancer
Koren, E., & Fuchs, Y. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0789 · Cited by 388
Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.
Cuello, M. A., Ettenberg, S. A., Clark, A. S., Keane, M., Posner, R. H., Nau, M. M., Dennis, P. A., & Lipkowitz, S. (2001) · PubMed · Cited by 370
Targeting death receptors in cancer with Apo2L/TRAIL
Kelley, S. K. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.02.006 · Cited by 370
Nature's TRAIL—On a Path to Cancer Immunotherapy
Smyth, M. J., Takeda, K., Hayakawa, Y., Peschon, J. J., van den Brink, M. R. M., & Yagita∥, H. (2003) · Immunity · doi:10.1016/s1074-7613(02)00502-2 · Cited by 360
ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
Condamine, T., Kumar, V., Ramachandran, I. R., Youn, J.-I., Celis, E., Finnberg, N., El-Deiry, W. S., Winograd, R., Vonderheide, R. H., English, N. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74056 · Cited by 365
Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Is an Inhibitor of Autoimmune Inflammation and Cell Cycle Progression
Song, K., Chen, Y., Göke, R., Wilmen, A., Seidel, C., Göke, A., Hilliard, B. A., & Chen, Y. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.7.1095 · Cited by 361
Apoptosis and Necrosis in the Liver
Guicciardi, M. E., Malhi, H., Mott, J. L., & Gores, G. J. (2013) · Comprehensive physiology · doi:10.1002/cphy.c120020 · Cited by 403
Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
Allen, J. E., Krigsfeld, G. S., Mayes, P. A., Patel, L., Dicker, D. T., Patel, A. S., Dolloff, N. G., Messaris, E. G., Scata, K. A., Wang, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004828 · Cited by 349
Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL−/− mice
Lamhamedi-Cherradi, S.-E., Zheng, S. J., Maguschak, K. A., Peschon, J. J., & Chen, Y. H. (2003) · Nature Immunology · doi:10.1038/ni894 · Cited by 350
Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential
Shankar, S. (2007) · Frontiers in bioscience · doi:10.2741/2432 · Cited by 343
Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL
Altucci, L., Rossin, A., Raffelsberger, W., Reitmair, A., Chomienne, C., & Gronemeyer, H. (2001) · Nature Medicine · doi:10.1038/89050 · Cited by 340
Expression and Function of TNF-Related Apoptosis-Inducing Ligand on Murine Activated NK Cells
Kayagaki, N., Yamaguchi, N., Nakayama, M., Takeda, K., Akiba, H., Tsutsui, H., Okamura, H., Nakanishi, K., Okumura, K., & Yagita∥, H. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.1906 · Cited by 338
Protein Complexes Activate Distinct Caspase Cascades in Death Receptor and Stress-Induced Apoptosis
Bratton, S. B., MacFarlane, M., Cain, K., & Cohen, G. M. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4835 · Cited by 334
MAPK/ERK Overrides the Apoptotic Signaling from Fas, TNF, and TRAIL Receptors
Tran, S. E. F., Holmström, T. H., Ahonen, M., Kähäri, V., & Eriksson, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010384200 · Cited by 329
The TRAIL to selective tumor death
French, L. E., & Tschopp, J. (1999) · Nature Medicine · doi:10.1038/5505 · Cited by 321
To kill a tumor cell: the potential of proapoptotic receptor agonists
Ashkenazi, A., & Herbst, R. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34359 · Cited by 324
The crosstalk between autophagy and apoptosis: where does this lead?
Gordy, C. L., & He, Y.-W. (2012) · Protein & Cell · doi:10.1007/s13238-011-1127-x · Cited by 325
Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
Ravi, R. K., Bedi, G. C., Engstrom, L., Zeng, Q., Mookerjee, B., Gélinas, C., Fuchs, E. J., & Bedi, A. (2001) · Nature Cell Biology · doi:10.1038/35070096 · Cited by 316
Insights into Programmed Cell Death through Structural Biology
Fesik, S. W. (2000) · Cell · doi:10.1016/s0092-8674(00)00119-7 · Cited by 317
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo
Pukac, L., Kanakaraj, P., Humphreys, R., Alderson, R., Bloom, M., Sung, C., Riccobene, T., Johnson, R., Fiscella, M., Mahoney, A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602487 · Cited by 306
Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2
Mérino, D., Lalaoui, N., Morizot, A., Schneider, P., Solary, É., & Micheau, O. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00520-06 · Cited by 306
TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK Pathways
Secchiero, P., Gonelli, A., Carnevale, E., Milani, D., Pandolfi, A., Zella, D., & Zauli, G. (2003) · Circulation · doi:10.1161/01.cir.0000062702.60708.c4 · Cited by 303
Onto better TRAILs for cancer treatment
de Miguel, D., Lemke, J., Anel, A., Walczak, H., & Martínez‐Lostao, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2015.174 · Cited by 308
Self-citation
Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics
Krakstad, C., & Chekenya, M. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-135 · Cited by 310
Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL)
Nitsch, R., Bechmann, I., Deisz, R. A., Haas, D., Lehmann, T.-N., Wendling, U., & Zipp, F. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02659-3 · Cited by 301
Following TRAIL’s path in the immune system
Falschlehner, C., Schaefer, U., & Walczak, H. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03058.x · Cited by 312
Self-citation
Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system
Eißner, G., Kölch, W., & Scheurich, P. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.011 · Cited by 303
Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer
Chen, X., Thakkar, H., Tyan, F., Gim, S., Robinson, H. M., Lee, C., Pandey, S., Nwokorie, C., Onwudiwe, N. C., & Srivastava, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204736 · Cited by 298
Cytokines, Inflammation and Colon Cancer
Klampfer, L. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795538066 · Cited by 297
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer
Garofalo, M., Quintavalle, C., Leva, G. D., Zanca, C., Romano, G., Taccioli, C., Liu, C. G., Croce, C. M., & Condorelli, G. (2008) · Oncogene · doi:10.1038/onc.2008.6 · Cited by 291
Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.
Leverkus, M., Neumann, M., Mengling, T., Rauch, C. T., Bröcker, E. B., Krammer, P. H., & Walczak, H. (2000) · PubMed · Cited by 288
Self-citation
Cell surface Death Receptor signaling in normal and cancer cells
Özören, N., & El‐Deiry, W. S. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00131-1 · Cited by 292
Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling
Kelley, R. F., Tótpál, K., Lindstrom, S. H., Mathieu, M. A., Billeci, K. L., DeForge, L. E., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 279
Structural principles of tumor necrosis factor superfamily signaling
Vanamee, É. S., & Faustman, D. L. (2018) · Science Signaling · doi:10.1126/scisignal.aao4910 · Cited by 284
Apoptosis-based therapies and drug targets
Fischer, U., & Schulze‐Osthoff, K. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401556 · Cited by 283
TRAIL/Apo-2L: Mechanisms and Clinical Applications in Cancer
Srivastava, R. K. (2001) · Neoplasia · doi:10.1038/sj.neo.7900203 · Cited by 279
On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
Dimberg, L. Y., Anderson, C. K., Camidge, D. R., Behbakht, K., Thorburn, A. M., & Ford, H. L. (2012) · Oncogene · doi:10.1038/onc.2012.164 · Cited by 280
TRAIL on trial: preclinical advances in cancer therapy
Stuckey, D. W., & Shah, K. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.08.007 · Cited by 277
Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis
Hinz, S., Trauzold, A., Boenicke, L., Sandberg, C., Beckmann, S., Bayer, E., Walczak, H., Kalthoff, H., & Ungefroren, H. (2000) · Oncogene · doi:10.1038/sj.onc.1203936 · Cited by 275
Self-citation
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape
DeSelm, C. J., Palomba, M. L., Yahalom, J., Hamieh, M., Eyquem, J., Rajasekhar, V. K., & Sadelain, M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.008 · Cited by 280
TRAIL receptor signalling and modulation: Are we on the right TRAIL?
Mahalingam, D., Szegezdi, É., Keane, M., de Jong, S., & Samali, A. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.11.006 · Cited by 271

Authors: Walczak, H., Miller, R. E., Ariail, K., Gliniak, B., Griffith, T. S., Kubin, M., Chin, W., Jones, J., Woodward, A., Le, T., Smith, C., Smolak, P., Goodwin, R. G., Rauch, C. T., Schuh, J. C. L., & Lynch, D. H.
Corresponding author: Lynch, David H.
ORCID: Walczak, Henning
Miller, Robert E.
Griffith, Thomas S.
Smith, Craig
Schuh, JoAnn C.L.
Lynch, David H.
Venue: Nature Medicine
Publisher: Springer Science and Business Media LLC
Published: 1999-02
Volume: 5
Issue: 2
Pages: 157-163
ISSN: 1078-8956 (ISSN-L)
1546-170X
DOI: 10.1038/5517
OpenAlex: W1484817497
Cited by: 2,497
References: 48
Citations by year: 2026: 20 · 2025: 24 · 2024: 33 · 2023: 58 · 2022: 47 · 2021: 57 · 2020: 57 · 2019: 63 · 2018: 64 · 2017: 73 · 2016: 76 · 2015: 80 · 2014: 84 · 2013: 94 · 2012: 96
FWCI: 41.34
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords: TRAIL, tumor necrosis factor-related apoptosis-inducing ligand, leucine zipper, Fas ligand, apoptosis, tumor growth inhibition, hepatotoxicity, SCID mice, TNF receptor, cancer therapy
MeSH terms: Animals, Antineoplastic Agents, Dose-Response Relationship, Drug, Humans, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Protein Conformation, Tumor Cells, Cultured, Tumor Necrosis Factor-alpha, Mice, SCID, Apoptosis, Apoptosis Regulatory Proteins, Mice, TNF-Related Apoptosis-Inducing Ligand, Fas Ligand Protein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks